The estimated Net Worth of Wei Peu Zen is at least $7.51 Tisíc dollars as of 9 September 2019. Wei Zen owns over 40,000 units of Emmaus Life Sciences Incorporation stock worth over $7,506 and over the last 5 years he sold EMMA stock worth over $0. In addition, he makes $0 as Director at Emmaus Life Sciences Incorporation.
Sign up
Wei Zen EMMA stock SEC Form 4 insiders trading
Wei has made over 5 trades of the Emmaus Life Sciences Incorporation stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 40,000 units of EMMA stock worth $170,000 on 9 September 2019.
The largest trade he's ever made was buying 52,892 units of Emmaus Life Sciences Incorporation stock on 4 September 2019 worth over $205,750. On average, Wei trades about 12,354 units every 1 days since 2019. As of 9 September 2019 he still owns at least 375,308 units of Emmaus Life Sciences Incorporation stock.
You can see the complete history of Wei Zen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wei Peu Zen biography
Wei Peu Zen is the Director at Emmaus Life Sciences Incorporation.
How old is Wei Zen?
Wei Zen is 67, he's been the Director of Emmaus Life Sciences Incorporation since 2019. There are 1 older and 12 younger executives at Emmaus Life Sciences Incorporation. The oldest executive at Emmaus Life Sciences Incorporation is Ian Zwicker, 71, who is the Director.
What's Wei Zen's mailing address?
Wei's mailing address filed with the SEC is 21250 HAWTHORNE BLVD., SUITE 800, , TORRANCE, CA, 90503.
Insiders trading at Emmaus Life Sciences Incorporation
Over the last 5 years, insiders at Emmaus Life Sciences Incorporation have traded over $1,625 worth of Emmaus Life Sciences Incorporation stock and bought 2,618,727 units worth $3,075,792 . The most active insiders traders include Yutaka Niihara, Willis C Lee a Seah H. Lim. On average, Emmaus Life Sciences Incorporation executives and independent directors trade stock every 10 days with the average trade being worth of $325. The most recent stock trade was executed by Willis C Lee on 26 February 2024, trading 115,200 units of EMMA stock currently worth $14,976.
What does Emmaus Life Sciences Incorporation do?
emmaus life sciences, inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. we are initially focusing our product development efforts in sickle cell disease, a genetic disorder. our lead product candidate is an oral pharmaceutical grade l-glutamine treatment that demonstrated positive clinical results in our completed phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia.
What does Emmaus Life Sciences Incorporation's logo look like?
Complete history of Wei Zen stock trades at Emmaus Life Sciences Incorporation
Emmaus Life Sciences Incorporation executives and stock owners
Emmaus Life Sciences Incorporation executives and other stock owners filed with the SEC include:
-
Dr. Yutaka Niihara M.D., M.P.H, M.P.H.,
Chairman & CEO -
Yasushi Nagasaki CPA, CPA,
Chief Financial Officer -
Willis C. Lee M.S.,
Vice Chairman & COO -
Ian Zwicker,
Director -
Wei Peu Zen,
Director -
Jane Wood,
Director -
Masaharu Osato,
Director -
Robert Dickey,
Director -
Yasushi Nagasaki,
Interim Chief Financial Officer -
Willis Lee,
Vice Chairman of the Board, Chief Operating Officer -
Lan Tran,
President, Chief Administrative Officer -
Yutaka Niihara,
Chairman of the Board, Chief Executive Officer -
S. Steven Lee,
Independent Consultant -
Kurt H. Kruger M.B.A., M.S.,
Consultant -
Dr. Charles W. Stark Pharm.D., Pharm.D,
Sr. VP of Medical Affairs, Clinical, Regulatory -
Dale E. Short J.D.,
Gen. Counsel -
George Sekulich,
Sr. VP of Global Commercialization & Chief Information Officer -
Charles William Stark,
CSO & EVP Clinical Development -
Seah H. Lim,
Director -
Alfred Fu Kong Lui,
Director -
George Sekulich,
Co-President & CCO